Defined Dose (DDD) is not specified in the WHO registry, namely imatinib, which probably does not have a DDD due to the different indications depending on the type of cancer. We further excluded 3 APIs where the referent was defined as a different molecule than the API included in the decree (e.g isosorbide dinitrate versus isosorbide mononitrate), or the referents defined in the decree were already unbranded generics (digoxin and methotrexate). Later, we excluded 7 APIs that did not have sales of any pharmaceutical product with conventional-release (phenytoin, diclofenac, fosamprenavir, indinavir, saquinavir, stavudine and valproic acid: found only in modified-release).
Also, 3 APIs under an existing patent during the study period were excluded: atazanavir (currently under patent), tenofovir (patent expired during 2017), and efavirenz (patent expired during 2014).
We further excluded 6 APIs in which the referent was not sold during the study period (metoclopramide, glibenclamide, chlorphenamine, cloxacillin, furosemide and ciprofloxacin), and 6
APIs that, although the referent was sold, we could not find sales of bioequivalent medicines during the study period (abacavir, lamivudine, nevirapine, ritonavir, clomiphene, and carbamazepine).
Finally, we excluded 1 API whose sales level was very small and, in fact, is no longer sold in the Chilean market (biperiden). 
